Saumya Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saumya Das has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
13 shared publications Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, KnowledgePark- II, Greater Noida, 2201306, Uttar Pradesh, India
5 shared publicationsAyushi Goel
Noida Institute of Engineering and Technology (Pharmacy Institute) PHARMACOLOGY Greater Noida India
3 shared publications- Pankaj Kumar Tyagi
Department of Biotechnology, Noida Institute of Engineering and Technology, 19 KnowledgePark-II, Institutional Area, Greater Noida-201306, Uttar Pradesh, India
3 shared publications Antra Sinha
Noida Institute of Engineering and Technology (Pharmacy Institute) PHARMACOLOGY Greater Noida India
2 shared publications- Archna Singh
Department of Pharmacology Noida Institute of Engineering and Technology (Pharmacy Institute) Greater Noida Uttar Pradesh India
2 shared publications
Latest Publications
- 3 November 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 27
Rapid-Acting Antidepressants: Targeting Neuroplasticity Beyond Monoamines
Depression remains a leading cause of morbidity worldwide, with conventional monoaminergic antidepressants such as SSRIs and SNRIs limited by delayed onset and high rates of treatment resistance. Novel approaches that modulate neuroplasticity, particularly NMDA receptor antagonists like ketamine, have demonstrated rapid efficacy in treatment-resistant depression. Ketamine relieves symptoms within hours by promoting glutamate release, AMPA receptor activation, BDNF–TrkB signaling, and mTOR pathway engagement, leading to synaptic remodeling. This review focuses on ketamine as an adjunct or alternative to monoaminergic therapies, highlighting mechanistic pathways of synaptic scaling and dendritic spine formation. Comparative insights into psychedelics, neurosteroids, and investigational NMDA modulators are also discussed, with emphasis on translational limitations, biomarker feasibility, and ethical challenges in digital therapeutics.
- 3 November 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 27
Rapid-Acting Antidepressants: Targeting Neuroplasticity Beyond Monoamines
Depression remains a leading cause of morbidity worldwide, with conventional monoaminergic antidepressants such as SSRIs and SNRIs limited by delayed onset and high rates of treatment resistance. Novel approaches that modulate neuroplasticity, particularly NMDA receptor antagonists like ketamine, have demonstrated rapid efficacy in treatment-resistant depression. Ketamine relieves symptoms within hours by promoting glutamate release, AMPA receptor activation, BDNF–TrkB signaling, and mTOR pathway engagement, leading to synaptic remodeling. This review focuses on ketamine as an adjunct or alternative to monoaminergic therapies, highlighting mechanistic pathways of synaptic scaling and dendritic spine formation. Comparative insights into psychedelics, neurosteroids, and investigational NMDA modulators are also discussed, with emphasis on translational limitations, biomarker feasibility, and ethical challenges in digital therapeutics.
- Open Access
- 30 October 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 5 (42) , 2019
Polyherbal Formulation Development and Therapeutic Assessment for the Management of Type 2 Diabetes Mellitus
Background: Type 2 diabetes mellitus (T2DM) is a worldwide epidemic that affects more than 530 million people, where traditional single-target based therapy can often have side effects, affordability issues, and fail to consider the multifactorial nature of the disease. Phytochemical synergism in polyherbal formulations is a promising option, as it allows them to address multiple pathogenic pathways. The present study was undertaken to formulate and test a polyherbal tablet of Syzygium cumini, Allium sativum, Moringa oleifera and Camellia sinensis for T2DM. For the method, the extracts were prepared by using hydroalcoholic extract procedure, concentrated and lyophilized for four plant materials. The tablets were optimized by using 3² full factorial design technique followed by direct compression method for the formulation of the polyherbal tablets.The polyherbal tablets were formulated by direct compression method and optimized by 3² full factorial design technique. Qualitative phytochemical screening and quantitative estimation of bioactive markers (quercetin, ellagic acid, alliin, EGCG and chlorogenic acid) using HPTLC and HPLC and physicochemical characterization of the extracts and formulation were carried out. Antidiabetic activity was determined by the ability of the extract to inhibit α-amylase and α-glucosidase, and antioxidant activity was determined by using DPPH and FRAP methods. The combination index (CI) method was used to determine synergistic interactions. Results: The polyherbal formulation had a wide phytochemical spectrum, with significant levels of quercetin (1.52 ± 0.05 mg/tablet), EGCG (1.41 ± 0.04 mg/tablet), chlorogenic acid (0.97 ± 0.03 mg/tablet), ellagic acid (0.75 ± 0.03 mg/tablet), and alliin (0.58 ± 0.02 mg/tablet). The optimized tablets had excellent physicochemical properties, with hardness 6.4 ± 0.5kg/cm² and friability 0.68 ± 0.12% and the disintegration time was 6.2 ± 0.8min. It exhibited strong α-amylase inhibitory activity (IC₅₀: 28.6 ± 1.3 µg/mL) and α-glucosidase inhibitory activity (IC₅₀: 18.2 ± 0.9 µg/mL) compared to the standard drug acarbose. It also exhibited superior antioxidant activity (DPPH IC₅₀: 18.4 ± 0.9 µg/mL; FRAP: 456.2 ± 19.3 µmol Fe²⁺/g). Combination index analysis showed that all activities tested exhibited synergistic interactions (CI: 0.58–0.72). Conclusion: The polyherbal formulation exhibited considerable in vitro antidiabetic and antioxidant potential via synergistic multi-target mechanism, establishing its therapeutic potential as a safe, effective and economical strategy for diabetic management of T2DM. These results indicate that they need further in vivo and clinical testing.
- 30 October 2026
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 5 (42) , 2019
Open AccessPolyherbal Formulation Development and Therapeutic Assessment for the Management of Type 2 Diabetes Mellitus
Background: Type 2 diabetes mellitus (T2DM) is a worldwide epidemic that affects more than 530 million people, where traditional single-target based therapy can often have side effects, affordability issues, and fail to consider the multifactorial nature of the disease. Phytochemical synergism in polyherbal formulations is a promising option, as it allows them to address multiple pathogenic pathways. The present study was undertaken to formulate and test a polyherbal tablet of Syzygium cumini, Allium sativum, Moringa oleifera and Camellia sinensis for T2DM. For the method, the extracts were prepared by using hydroalcoholic extract procedure, concentrated and lyophilized for four plant materials. The tablets were optimized by using 3² full factorial design technique followed by direct compression method for the formulation of the polyherbal tablets.The polyherbal tablets were formulated by direct compression method and optimized by 3² full factorial design technique. Qualitative phytochemical screening and quantitative estimation of bioactive markers (quercetin, ellagic acid, alliin, EGCG and chlorogenic acid) using HPTLC and HPLC and physicochemical characterization of the extracts and formulation were carried out. Antidiabetic activity was determined by the ability of the extract to inhibit α-amylase and α-glucosidase, and antioxidant activity was determined by using DPPH and FRAP methods. The combination index (CI) method was used to determine synergistic interactions. Results: The polyherbal formulation had a wide phytochemical spectrum, with significant levels of quercetin (1.52 ± 0.05 mg/tablet), EGCG (1.41 ± 0.04 mg/tablet), chlorogenic acid (0.97 ± 0.03 mg/tablet), ellagic acid (0.75 ± 0.03 mg/tablet), and alliin (0.58 ± 0.02 mg/tablet). The optimized tablets had excellent physicochemical properties, with hardness 6.4 ± 0.5kg/cm² and friability 0.68 ± 0.12% and the disintegration time was 6.2 ± 0.8min. It exhibited strong α-amylase inhibitory activity (IC₅₀: 28.6 ± 1.3 µg/mL) and α-glucosidase inhibitory activity (IC₅₀: 18.2 ± 0.9 µg/mL) compared to the standard drug acarbose. It also exhibited superior antioxidant activity (DPPH IC₅₀: 18.4 ± 0.9 µg/mL; FRAP: 456.2 ± 19.3 µmol Fe²⁺/g). Combination index analysis showed that all activities tested exhibited synergistic interactions (CI: 0.58–0.72). Conclusion: The polyherbal formulation exhibited considerable in vitro antidiabetic and antioxidant potential via synergistic multi-target mechanism, establishing its therapeutic potential as a safe, effective and economical strategy for diabetic management of T2DM. These results indicate that they need further in vivo and clinical testing.
- 17 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-19
Insight into Ulcerative Colitis and Associated Diarrhea: Exploring the Interplay of Cellular and Molecular Axis with Advancement in Treatments
Ulcerative Colitis (UC)-associated diarrhea is a debilitating symptom of persistent intestinal inflammation that significantly reduces a patient's quality of life. Epithelial ion transport failure, tight junction remodeling, dysregulated mucus secretion, immunological overactivation, gut microbiota dysbiosis, and mitochondrial oxidative stress all interact intimately to cause its pathogenesis. While cytokine-mediated suppression of ENaC, NHE3 (Na+/H+ exchanger 3), DRA (SLC26A3), and PAT1 (SLC26A6) significantly reduces fluid and electrolyte absorption, chronic inflammation promotes "claudin switching" and tight junction breakdown, increasing paracellular permeability. Mucosal barrier failure is sustained and inflammatory cascades are intensified by concurrent deregulation of the NF-κB, JAK/STAT, and PXR signaling pathways. Recent findings highlight the critical role of immune-microbiota crosstalk and reactive oxygen species formed from mitochondria in sustaining this pathogenic cycle. Recent developments in biologics, targeted small molecules, colon-specific hydrogels, and nanomedicine offer potential approaches for site-specific drug delivery, immunologic control, and epithelial barrier restoration, in addition to traditional pharmacotherapies. This review highlights future options for tailored, multi-targeted therapies. It provides a framework for mechanism-guided management of UC-associated diarrhea by synthesizing existing mechanistic insights and translational therapeutic advancements.
- 17 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Advances in Inflammation & Allergy Drug Discovery
- Vol. 20, 1-19
Insight into Ulcerative Colitis and Associated Diarrhea: Exploring the Interplay of Cellular and Molecular Axis with Advancement in Treatments
Ulcerative Colitis (UC)-associated diarrhea is a debilitating symptom of persistent intestinal inflammation that significantly reduces a patient's quality of life. Epithelial ion transport failure, tight junction remodeling, dysregulated mucus secretion, immunological overactivation, gut microbiota dysbiosis, and mitochondrial oxidative stress all interact intimately to cause its pathogenesis. While cytokine-mediated suppression of ENaC, NHE3 (Na+/H+ exchanger 3), DRA (SLC26A3), and PAT1 (SLC26A6) significantly reduces fluid and electrolyte absorption, chronic inflammation promotes "claudin switching" and tight junction breakdown, increasing paracellular permeability. Mucosal barrier failure is sustained and inflammatory cascades are intensified by concurrent deregulation of the NF-κB, JAK/STAT, and PXR signaling pathways. Recent findings highlight the critical role of immune-microbiota crosstalk and reactive oxygen species formed from mitochondria in sustaining this pathogenic cycle. Recent developments in biologics, targeted small molecules, colon-specific hydrogels, and nanomedicine offer potential approaches for site-specific drug delivery, immunologic control, and epithelial barrier restoration, in addition to traditional pharmacotherapies. This review highlights future options for tailored, multi-targeted therapies. It provides a framework for mechanism-guided management of UC-associated diarrhea by synthesizing existing mechanistic insights and translational therapeutic advancements.
- 8 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23, 1-14
AI Frameworks for the Early Detection and Management of Diabetic Retinopathy: A Real-World Application
Diabetic retinopathy (DR) is a condition that progressively affects the microvasculature, commonly seen in individuals with diabetes, which is a leading cause of visual impairment across the globe. Approximately one-third of people with diabetes will eventually develop DR, and it remains a public health issue because the retinal damage is irreversible if the disease continues to go undiagnosed and untreated. Although various screening methods exist, including fundus photography and optical coherence tomography (OCT), they are often limited as a result of availability and expertise required for diagnosis and management. Recent advancements in artificial intelligence (AI) are transforming DR screening and diagnosis. AI has demonstrated the potential to automate retinal image evaluation with accuracies that, in some studies, approach or exceed existing standards of care; however, reported performance varies across algorithms, datasets, and clinical settings, highlighting the need for cautious interpretation and further validation in diverse populations. Machine learning (ML) & deep learning (DL) models, particularly convolutional neural networks (CNNs), have been found to have excellent performance in identifying DR-related abnormalities, including mild, moderate, and severe DR, and diabetic macular edema, at sensitivities and specificities exceeding traditional screening. AI tools under various names, such as IDx-DR, EyeArt, and Google’s AI algorithm, are quick and price-effective tests using an AI solution for early diagnosis of DR in either developed or developing economies. In addition, AI can also support predictive analytics, risk stratification, and treatment decision-making, so that ophthalmologists can provide patients with better management options. Importantly, AI also comes with its own challenges, such as data harmonization and regulatory approval for deploying AI in clinical care. This review will focus on the existing literature on the applications of AI in diagnosing and management of DR and will outline the importance of this innovation.
- 8 September 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23, 1-14
AI Frameworks for the Early Detection and Management of Diabetic Retinopathy: A Real-World Application
Diabetic retinopathy (DR) is a condition that progressively affects the microvasculature, commonly seen in individuals with diabetes, which is a leading cause of visual impairment across the globe. Approximately one-third of people with diabetes will eventually develop DR, and it remains a public health issue because the retinal damage is irreversible if the disease continues to go undiagnosed and untreated. Although various screening methods exist, including fundus photography and optical coherence tomography (OCT), they are often limited as a result of availability and expertise required for diagnosis and management. Recent advancements in artificial intelligence (AI) are transforming DR screening and diagnosis. AI has demonstrated the potential to automate retinal image evaluation with accuracies that, in some studies, approach or exceed existing standards of care; however, reported performance varies across algorithms, datasets, and clinical settings, highlighting the need for cautious interpretation and further validation in diverse populations. Machine learning (ML) & deep learning (DL) models, particularly convolutional neural networks (CNNs), have been found to have excellent performance in identifying DR-related abnormalities, including mild, moderate, and severe DR, and diabetic macular edema, at sensitivities and specificities exceeding traditional screening. AI tools under various names, such as IDx-DR, EyeArt, and Google’s AI algorithm, are quick and price-effective tests using an AI solution for early diagnosis of DR in either developed or developing economies. In addition, AI can also support predictive analytics, risk stratification, and treatment decision-making, so that ophthalmologists can provide patients with better management options. Importantly, AI also comes with its own challenges, such as data harmonization and regulatory approval for deploying AI in clinical care. This review will focus on the existing literature on the applications of AI in diagnosing and management of DR and will outline the importance of this innovation.
- Open Access
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1593-1608
Unraveling the Pharmacognostic and Mechanistic Landscape of Bombax ceiba L.: Exploring its Phytoconstituents and Therapeutic Potentials
Background: Bombax ceiba (B. ceiba) L. is an important plant in the Malvaceae family, widely distributed across tropical and subtropical areas of Africa, Asia and Australia. The medicinal properties of the plant are highly valued under various forms of traditional medicines such as Ayurveda, Siddha, Unani, and others. It has been used to treat gastrointestinal, skin, urinary, and wound-healing ailments for a long time. The experimental literature is increasingly becoming popular, but a focused integration linking pharmacognostic identity to mechanistic pharmacology is largely missing. Aim: The objective of the mini-review is to combine classical pharmacognosy with molecular pharmacology of B. ceiba. As a future orientation in drug development, the morphological authentication, phytochemical characterisation and diversity and the experimentally deciphered bioactivities together with the impact of innovative nano-formulation may be brought into a unified document defined in a “bench-to-biological-pathway”. Methods: The pharmacognostic characterisation, herbal medicine and ethnopharmacology, phytochemistry, and pharmacology of species belonging to the genus Bombax, specifically B. ceiba, were systematically reviewed. This allowed us to assess its medical utility and market potential in the context of a rapidly evolving functional food industry. Relevant information was included in an operational model of pharmacognosy phytochemistry mechanism. Result: Stigmasterol, β-amyrin palmitate, lupeol palmitate, and malvalic acid are compounds purified from the parts of B. ceiba. The plant is abundantly loaded with lupeol, mangiferin, β-sitosterol, quercetin and its derivatives, shamimin, anthocyanins, naphthoquinones, and others and also possesses a vast scope of applications in cosmetics, pharmacy, and food industry. Conclusion: B. ceiba emerges as a good multi-target ethnomedicine; it has pharmacognostic identity and good pharmacological preclinical evidence. According to findings, there is a correlation between conventional uses and modulation of the NF-κB, Nrf2, MAPK, and AMPK pathways Consequently, it seems likely a good candidate for phytopharmaceutical preparation. In future perspective, it is important to establish protocols for extracting the plant, study pharmacokinetic, and implement controlled clinical trials to transform this wealth into evidence-based and easily perceptible therapeutic agents. Major Findings: B. ceiba L. covers key bioactives — lupeol, mangiferin, β-sitosterol, and quercetin derivatives — that modulate NF-κB, Nrf2, MAPK, and AMPK pathways, granting anti-inflammatory, antioxidant, hepatoprotective, and antidiabetic activities, though the absence of controlled clinical trials and standardised extracts remains a critical translational gap demanding systematic pharmacokinetic and clinical validation.
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1593-1608
Open AccessUnraveling the Pharmacognostic and Mechanistic Landscape of Bombax ceiba L.: Exploring its Phytoconstituents and Therapeutic Potentials
Background: Bombax ceiba (B. ceiba) L. is an important plant in the Malvaceae family, widely distributed across tropical and subtropical areas of Africa, Asia and Australia. The medicinal properties of the plant are highly valued under various forms of traditional medicines such as Ayurveda, Siddha, Unani, and others. It has been used to treat gastrointestinal, skin, urinary, and wound-healing ailments for a long time. The experimental literature is increasingly becoming popular, but a focused integration linking pharmacognostic identity to mechanistic pharmacology is largely missing. Aim: The objective of the mini-review is to combine classical pharmacognosy with molecular pharmacology of B. ceiba. As a future orientation in drug development, the morphological authentication, phytochemical characterisation and diversity and the experimentally deciphered bioactivities together with the impact of innovative nano-formulation may be brought into a unified document defined in a “bench-to-biological-pathway”. Methods: The pharmacognostic characterisation, herbal medicine and ethnopharmacology, phytochemistry, and pharmacology of species belonging to the genus Bombax, specifically B. ceiba, were systematically reviewed. This allowed us to assess its medical utility and market potential in the context of a rapidly evolving functional food industry. Relevant information was included in an operational model of pharmacognosy phytochemistry mechanism. Result: Stigmasterol, β-amyrin palmitate, lupeol palmitate, and malvalic acid are compounds purified from the parts of B. ceiba. The plant is abundantly loaded with lupeol, mangiferin, β-sitosterol, quercetin and its derivatives, shamimin, anthocyanins, naphthoquinones, and others and also possesses a vast scope of applications in cosmetics, pharmacy, and food industry. Conclusion: B. ceiba emerges as a good multi-target ethnomedicine; it has pharmacognostic identity and good pharmacological preclinical evidence. According to findings, there is a correlation between conventional uses and modulation of the NF-κB, Nrf2, MAPK, and AMPK pathways Consequently, it seems likely a good candidate for phytopharmaceutical preparation. In future perspective, it is important to establish protocols for extracting the plant, study pharmacokinetic, and implement controlled clinical trials to transform this wealth into evidence-based and easily perceptible therapeutic agents. Major Findings: B. ceiba L. covers key bioactives — lupeol, mangiferin, β-sitosterol, and quercetin derivatives — that modulate NF-κB, Nrf2, MAPK, and AMPK pathways, granting anti-inflammatory, antioxidant, hepatoprotective, and antidiabetic activities, though the absence of controlled clinical trials and standardised extracts remains a critical translational gap demanding systematic pharmacokinetic and clinical validation.
- 11 May 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25, 1-24
Redefining Parkinson’s Care: The Promise of Nanotechnology and Artificial Intelligence
Introduction: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by the depletion of dopaminergic neurons and the buildup of α-synuclein aggregates, resulting in damaging motor and non-motor symptoms. Conventional therapies, comprising levodopa and dopamine agonists, give symptomatic relief but fail to terminate disease progression and are associated with long-term complications. Method and Materials: Relevant review papers and articles from the past were investigated. Certain factors, including early disease diagnosis, therapeutic efficacy in PD models, and predictive modeling of drug-nanoparticle interactions, were considered during the conduct of this research. This literature review is a comprehensive narrative of research articles obtained from various platforms, namely Scopus, PubMed, Google Scholar, and Research Gate. Inclusion and exclusion criteria were applied to filter out the suitable materials. Result: Artificial intelligence (AI) is emerging as a complementary tool, facilitating design-optimized nanocarriers and predicting drug interactions while emphasizing liposomes and metallic nanoparticles as important platforms for dopamine replacement, gene therapy, and neuroinflammation modulation. Discussion: Despite the progress made so far, clinical translation still has considerable challenges to overcome, including nanoparticle toxicity, scalability, long-term safety, and variability in AI model performance. Integration of AI with biologically relevant PK/PD models and personalized nanomedicine strategies should overcome such existing gaps and enhance the therapeutic reliability of nanomedicine. Conclusion: This review summarizes current advances in nanomedicine and AI-driven approaches for PD, discussing their mechanisms, therapeutic targets, and future perspectives in achieving disease-modifying interventions
- 11 May 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25, 1-24
Redefining Parkinson’s Care: The Promise of Nanotechnology and Artificial Intelligence
Introduction: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by the depletion of dopaminergic neurons and the buildup of α-synuclein aggregates, resulting in damaging motor and non-motor symptoms. Conventional therapies, comprising levodopa and dopamine agonists, give symptomatic relief but fail to terminate disease progression and are associated with long-term complications. Method and Materials: Relevant review papers and articles from the past were investigated. Certain factors, including early disease diagnosis, therapeutic efficacy in PD models, and predictive modeling of drug-nanoparticle interactions, were considered during the conduct of this research. This literature review is a comprehensive narrative of research articles obtained from various platforms, namely Scopus, PubMed, Google Scholar, and Research Gate. Inclusion and exclusion criteria were applied to filter out the suitable materials. Result: Artificial intelligence (AI) is emerging as a complementary tool, facilitating design-optimized nanocarriers and predicting drug interactions while emphasizing liposomes and metallic nanoparticles as important platforms for dopamine replacement, gene therapy, and neuroinflammation modulation. Discussion: Despite the progress made so far, clinical translation still has considerable challenges to overcome, including nanoparticle toxicity, scalability, long-term safety, and variability in AI model performance. Integration of AI with biologically relevant PK/PD models and personalized nanomedicine strategies should overcome such existing gaps and enhance the therapeutic reliability of nanomedicine. Conclusion: This review summarizes current advances in nanomedicine and AI-driven approaches for PD, discussing their mechanisms, therapeutic targets, and future perspectives in achieving disease-modifying interventions
- 12 March 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25
Microbiota-Gut-Brain Axis: A Novel Paradigm in the Neurobiology of Anxiety
Introduction: The gut microbiome and the central nervous system are intricately connected through a bidirectional communication system that plays a vital role in maintaining gut homeostasis and overall health. Disruptions in this interaction are linked to gastrointestinal and neuropsychiatric disorders, including anxiety. This review aims to provide a comprehensive analysis of the gut microbiota’s role in anxiety and evaluate the therapeutic potential of prebiotics. Methods: This review synthesizes recent literature from databases including PubMed, Scopus, Web of Science, and Google Scholar, focusing on the gut microbiota’s role in anxiety and the therapeutic potential of prebiotics. Results: The microbiota-gut-brain axis communicates through multiple pathways, including the vagus nerve, immune signaling, microbial metabolites, and the hypothalamic-pituitary-adrenal (HPA) axis. Prebiotics modulate these pathways by enhancing beneficial microbial populations and influencing the production of neuroactive compounds. Key molecular targets implicated in this communication include brain-derived neurotrophic factor (BDNF), glucocorticoid receptors, and shortchain fatty acids, which modulate neurotransmitters such as GABA and serotonin, and influence neuroinflammatory pathways implicated in anxiety pathophysiology. Discussion: The findings highlight the immunological, neurochemical, and endocrine mechanisms through which the gut microbiota interacts with neurophysiological systems. These mechanisms underscore the pharmacological potential of prebiotics in the management of psychiatric illnesses. Conclusion: The interplay between the gastrointestinal microbiota and neurophysiological systems provides key pharmacological insights into the potential of prebiotics as a therapeutic approach for managing psychiatric illnesses, detailing their mechanistic pathways and translational applications in clinical practice.
- 12 March 2026
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 25
Microbiota-Gut-Brain Axis: A Novel Paradigm in the Neurobiology of Anxiety
Introduction: The gut microbiome and the central nervous system are intricately connected through a bidirectional communication system that plays a vital role in maintaining gut homeostasis and overall health. Disruptions in this interaction are linked to gastrointestinal and neuropsychiatric disorders, including anxiety. This review aims to provide a comprehensive analysis of the gut microbiota’s role in anxiety and evaluate the therapeutic potential of prebiotics. Methods: This review synthesizes recent literature from databases including PubMed, Scopus, Web of Science, and Google Scholar, focusing on the gut microbiota’s role in anxiety and the therapeutic potential of prebiotics. Results: The microbiota-gut-brain axis communicates through multiple pathways, including the vagus nerve, immune signaling, microbial metabolites, and the hypothalamic-pituitary-adrenal (HPA) axis. Prebiotics modulate these pathways by enhancing beneficial microbial populations and influencing the production of neuroactive compounds. Key molecular targets implicated in this communication include brain-derived neurotrophic factor (BDNF), glucocorticoid receptors, and shortchain fatty acids, which modulate neurotransmitters such as GABA and serotonin, and influence neuroinflammatory pathways implicated in anxiety pathophysiology. Discussion: The findings highlight the immunological, neurochemical, and endocrine mechanisms through which the gut microbiota interacts with neurophysiological systems. These mechanisms underscore the pharmacological potential of prebiotics in the management of psychiatric illnesses. Conclusion: The interplay between the gastrointestinal microbiota and neurophysiological systems provides key pharmacological insights into the potential of prebiotics as a therapeutic approach for managing psychiatric illnesses, detailing their mechanistic pathways and translational applications in clinical practice.
- 9 March 2026
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22
Mechanistic Pathways and Bidirectional Relationship between Diabetes Mellitus and Anxiety
The clinical manifestations of anxiety and diabetes mellitus are increasingly recognized as significant global public health challenges. According to current investigations, diabetes and anxiety have a mutually reinforcing relationship in which the course and outcomes of each condition are influenced by the other. To investigate the complementary effects of diabetes and anxiety, including their influence on the onset and severity of each condition, a comprehensive literature review was conducted. This review highlights the incidence of type 2 diabetes (T2D) in the coexisting stage of sarcopenia (a comorbid condition). T2D is characterized by pathophysiological disturbances, including dysregulated insulin signaling, chronic hyperglycemia, chronic inflammation, oxidative stress, insulin resistance (IR), and dyslipidemia. These factors collectively impair brain neurotransmitter function and suppress brain-derived neurotrophic factor expression, thereby predisposing individuals to anxiety. Impaired autophagy further contributes to neuronal dysfunction and metabolic imbalance, exacerbating both anxiety and T2D. Conversely, anxiety contributes to the development of IR and T2D through biological, psychological, and behavioral pathways. Chronic psychological distress disrupts the hypothalamic–pituitary–adrenal (HPA) axis, elevating cortisol levels, which in turn promote IR and accelerate T2D onset. Epidemiological data show that anxiety and T2D co-occur at approximately twice the rate compared with their independent prevalence. This review outlines essential features for analyzing the intricate link between diabetes and anxiety, focusing on incidence, shared underlying mechanisms, and highlighting potential novel biomarkers and therapeutic targets implicated in both conditions. By synthesizing current evidence, it aims to provide insights into effective management strategies and identify research gaps to enhance understanding and care for individuals affected by both diseases, thereby guiding future investigations.
- 9 March 2026
- Published by Bentham Science Publishers Ltd. in Current Psychiatry Research and Reviews
- Vol. 22
Mechanistic Pathways and Bidirectional Relationship between Diabetes Mellitus and Anxiety
The clinical manifestations of anxiety and diabetes mellitus are increasingly recognized as significant global public health challenges. According to current investigations, diabetes and anxiety have a mutually reinforcing relationship in which the course and outcomes of each condition are influenced by the other. To investigate the complementary effects of diabetes and anxiety, including their influence on the onset and severity of each condition, a comprehensive literature review was conducted. This review highlights the incidence of type 2 diabetes (T2D) in the coexisting stage of sarcopenia (a comorbid condition). T2D is characterized by pathophysiological disturbances, including dysregulated insulin signaling, chronic hyperglycemia, chronic inflammation, oxidative stress, insulin resistance (IR), and dyslipidemia. These factors collectively impair brain neurotransmitter function and suppress brain-derived neurotrophic factor expression, thereby predisposing individuals to anxiety. Impaired autophagy further contributes to neuronal dysfunction and metabolic imbalance, exacerbating both anxiety and T2D. Conversely, anxiety contributes to the development of IR and T2D through biological, psychological, and behavioral pathways. Chronic psychological distress disrupts the hypothalamic–pituitary–adrenal (HPA) axis, elevating cortisol levels, which in turn promote IR and accelerate T2D onset. Epidemiological data show that anxiety and T2D co-occur at approximately twice the rate compared with their independent prevalence. This review outlines essential features for analyzing the intricate link between diabetes and anxiety, focusing on incidence, shared underlying mechanisms, and highlighting potential novel biomarkers and therapeutic targets implicated in both conditions. By synthesizing current evidence, it aims to provide insights into effective management strategies and identify research gaps to enhance understanding and care for individuals affected by both diseases, thereby guiding future investigations.
- 24 February 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22 (5) , 1-16
Integrative Insights into Cancer Progression: Molecular Mechanisms, Epigenetic Regulation, and Emerging Therapeutic Targets
Tumor biology has advanced significantly over the last century, mainly due to advances in cellular signaling pathways, genomics, and epigenomics. The study of cancer epigenetics, including DNA methylation, histone modifications, and non-coding RNAs, has shed light on regulatory disturbances that change chromatin structure and gene expression, promoting carcinogenesis. Beyond only genetic alterations, these discoveries uncover new pathways and potential treatment targets. The importance of immune cells, stromal connections, and signaling molecules in influencing tumor growth and resistance has also been highlighted by advancements in tumor microenvironment (TME) profiling. For example, the ERK/MEK/Raf pathway, which is frequently activated in HCC and other malignancies, underscores crucial links between growth factors and cell division, promoting oncogenesis across multiple organs. Advancements in targeted therapies, including small molecules and monoclonal antibodies, have introduced novel approaches to inhibit these pathways and improve patient outcomes, though challenges like therapeutic resistance persist. Emerging resistance mechanisms, such as the activation of alternative pathways, underscore the need for combination therapies and next-generation inhibitors. Furthermore, technologies, such as liquid biopsies using circulating tumor DNA (ctDNA) and computational models for personalized treatment, mark significant strides toward overcoming intratumoral heterogeneity and adaptive resistance. This comprehensive examination of tumor biology highlights the intricate interplay of epigenetic, genetic, and microenvironmental factors in cancer progression, underscoring the continued need for integrative research. Future oncological strategies will likely focus on a multidisciplinary approach, combining genomics, epigenetics, immune modulation, and bioinformatics to develop more effective, individualized therapies against cancer's complex and evolving landscape.
- 24 February 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22 (5) , 1-16
Integrative Insights into Cancer Progression: Molecular Mechanisms, Epigenetic Regulation, and Emerging Therapeutic Targets
Tumor biology has advanced significantly over the last century, mainly due to advances in cellular signaling pathways, genomics, and epigenomics. The study of cancer epigenetics, including DNA methylation, histone modifications, and non-coding RNAs, has shed light on regulatory disturbances that change chromatin structure and gene expression, promoting carcinogenesis. Beyond only genetic alterations, these discoveries uncover new pathways and potential treatment targets. The importance of immune cells, stromal connections, and signaling molecules in influencing tumor growth and resistance has also been highlighted by advancements in tumor microenvironment (TME) profiling. For example, the ERK/MEK/Raf pathway, which is frequently activated in HCC and other malignancies, underscores crucial links between growth factors and cell division, promoting oncogenesis across multiple organs. Advancements in targeted therapies, including small molecules and monoclonal antibodies, have introduced novel approaches to inhibit these pathways and improve patient outcomes, though challenges like therapeutic resistance persist. Emerging resistance mechanisms, such as the activation of alternative pathways, underscore the need for combination therapies and next-generation inhibitors. Furthermore, technologies, such as liquid biopsies using circulating tumor DNA (ctDNA) and computational models for personalized treatment, mark significant strides toward overcoming intratumoral heterogeneity and adaptive resistance. This comprehensive examination of tumor biology highlights the intricate interplay of epigenetic, genetic, and microenvironmental factors in cancer progression, underscoring the continued need for integrative research. Future oncological strategies will likely focus on a multidisciplinary approach, combining genomics, epigenetics, immune modulation, and bioinformatics to develop more effective, individualized therapies against cancer's complex and evolving landscape.
- 30 December 2025
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 16
Advances in Pharmacotherapeutic Strategies for Functional Gastrointestinal Disorders: Nanotechnology-Based Approaches and Future Therapeutic Frontiers
Introduction: Functional gastrointestinal disorders (FGIDs), including IBS, FD, and GERD, represent complex clinical entities characterized by the convergence of gut-brain axis dysfunction, aberrant visceral pain processing, immune activation, and microbial dysbiosis, leading to persistent gastrointestinal symptoms despite the absence of identifiable structural changes. Traditional pharmacological strategies, including antacids, proton pump inhibitors (PPIs), antispasmodics, prokinetics, and neuromodulators, often provide only partial relief and may cause adverse effects. Methodology: This review aimed to compile current pharmacological strategies and recent innovations, focusing on nanotechnology-based drug delivery systems, biologics, gene therapies, and microbiome-targeted interventions. Key preclinical and clinical findings were analyzed to assess therapeutic efficacy and the innovation of delivery strategies. Results: Recent advances have introduced biologics and nanotechnology-based drug delivery systems as promising therapies for FGIDs. Nanoparticles, such as lipid, polymeric, and inorganic types, offer improved drug stability, bioavailability, and site-specific delivery. Novel formulations, including ROS-responsive and mucus-penetrating particles, enable controlled, inflammation- targeted release with reduced toxicity. Functional agents, such as curcumin, berberine, and TNF-α siRNA, exhibit enhanced efficacy in preclinical IBD models when delivered via nanoparticles. Additionally, microbiome-based therapies, such as probiotics, synbiotics, and fecal microbiota transplantation, support modulation of the gut-brain axis and restoration of microbial balance. Discussion: Therapeutic approaches are shifting from symptomatic management to targeted and mechanism-based strategies. Precision medicine incorporating genomic, proteomic, and microbiome profiling offers the potential for personalized treatments. Conclusion: Emerging therapies, particularly NP-based systems and microbiome-centered interventions, offer a transformative potential in FGID management. However, challenges in regulatory, accessibility, and combination therapy validation must be addressed for clinical translation.
- 30 December 2025
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 16
Advances in Pharmacotherapeutic Strategies for Functional Gastrointestinal Disorders: Nanotechnology-Based Approaches and Future Therapeutic Frontiers
Introduction: Functional gastrointestinal disorders (FGIDs), including IBS, FD, and GERD, represent complex clinical entities characterized by the convergence of gut-brain axis dysfunction, aberrant visceral pain processing, immune activation, and microbial dysbiosis, leading to persistent gastrointestinal symptoms despite the absence of identifiable structural changes. Traditional pharmacological strategies, including antacids, proton pump inhibitors (PPIs), antispasmodics, prokinetics, and neuromodulators, often provide only partial relief and may cause adverse effects. Methodology: This review aimed to compile current pharmacological strategies and recent innovations, focusing on nanotechnology-based drug delivery systems, biologics, gene therapies, and microbiome-targeted interventions. Key preclinical and clinical findings were analyzed to assess therapeutic efficacy and the innovation of delivery strategies. Results: Recent advances have introduced biologics and nanotechnology-based drug delivery systems as promising therapies for FGIDs. Nanoparticles, such as lipid, polymeric, and inorganic types, offer improved drug stability, bioavailability, and site-specific delivery. Novel formulations, including ROS-responsive and mucus-penetrating particles, enable controlled, inflammation- targeted release with reduced toxicity. Functional agents, such as curcumin, berberine, and TNF-α siRNA, exhibit enhanced efficacy in preclinical IBD models when delivered via nanoparticles. Additionally, microbiome-based therapies, such as probiotics, synbiotics, and fecal microbiota transplantation, support modulation of the gut-brain axis and restoration of microbial balance. Discussion: Therapeutic approaches are shifting from symptomatic management to targeted and mechanism-based strategies. Precision medicine incorporating genomic, proteomic, and microbiome profiling offers the potential for personalized treatments. Conclusion: Emerging therapies, particularly NP-based systems and microbiome-centered interventions, offer a transformative potential in FGID management. However, challenges in regulatory, accessibility, and combination therapy validation must be addressed for clinical translation.